These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 28289548

  • 1. The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.
    Brown GC, Brown MM, Lieske HB, Turpcu A, Rajput Y.
    Int J Retina Vitreous; 2017; 3():5. PubMed ID: 28289548
    [Abstract] [Full Text] [Related]

  • 2. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 3. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 4. A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS.
    Int J Retina Vitreous; 2015 Oct; 1():19. PubMed ID: 27847612
    [Abstract] [Full Text] [Related]

  • 5. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 6. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.
    Ophthalmology; 2013 Dec; 120(12):2367-2376. PubMed ID: 24246824
    [Abstract] [Full Text] [Related]

  • 7. Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Gierhart D, Olk RJ.
    Ophthalmol Ther; 2023 Oct; 12(5):2583-2608. PubMed ID: 37430077
    [Abstract] [Full Text] [Related]

  • 8. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
    Brown GC, Brown MM, Chaudhry I, Stein JD.
    JAMA Ophthalmol; 2021 Apr 01; 139(4):389-397. PubMed ID: 33538789
    [Abstract] [Full Text] [Related]

  • 9. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States.
    Brown GC, Brown MM, Rapuano SB, Boyer D.
    Am J Ophthalmol; 2021 Mar 01; 223():405-429. PubMed ID: 32681907
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr 01; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 12. Financial return-on-investment of ophthalmic interventions: a new paradigm.
    Brown MM, Brown GC, Lieske HB, Lieske PA.
    Curr Opin Ophthalmol; 2014 May 01; 25(3):171-6. PubMed ID: 24638114
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec 01; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Trans Am Ophthalmol Soc; 2013 Sep 01; 111():56-69. PubMed ID: 24167325
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.